Events

Loading Events

« All Events

  • This event has passed.

EvoNexus & Wilson Sonsini Business Development & Fundraising in the Current Environment SIG

September 6, 2023 @ 5:00 pm - 7:00 pm PDT

Free

EvoNexus & Wilson Sonsini Business Development & Fundraising in the Current Environment SIG


AN EVONEXUS & WILSON SONSINI EVENT

Join us at the EvoNexus San Diego HQ for the Business Development & Fundraising in the Current Environment SIG on Wednesday, September 6th from 5-7PM. Secure your reservation ASAP as seating will be limited!

Register Here!



EvoNexus & Wilson Sonsini Business Development & Fundraising in the Current Environment

Date: Wed Sep 06 2023

Time: 5-7PM (Pacific Daylight Time)

Location: 5015 Shoreham Place Suite 150, San Diego, CA 92122

Join us for an exciting in-person event where EvoNexus and Wilson Sonsini will be discussing business development and fundraising in the current landscape. Discover valuable insights, strategies, and trends that can help your business thrive. Whether you are an entrepreneur, startup founder, or simply interested in the world of business, this event offers a unique opportunity to network, learn, and gain inspiration from industry experts.

Don’t miss out on this chance to connect with like-minded individuals and gain valuable knowledge to take your business to the next level. Mark your calendars and get ready for an evening filled with insightful discussions, inspiring presentations, and valuable connections!

Register Here!



MODERATOR

Zachary Myers, Partner, Wilson Sonsini Goodrich & Rosati

Zach Myers is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he specializes in corporate and securities law, including, venture capital financings, mergers and acquisitions, and public company representation. Zach has extensive experience representing private and public companies in the technology and life sciences sectors. He has worked with a number of Southern California’s most exciting companies, from startup and emerging companies to large public companies. He has also assisted numerous clients that have gone public, listing on the New York Stock Exchange and NASDAQ markets. He is a board member of EvoNexus and San Diego Venture Group, which is now known as Connect, where he serves on the Life Sciences Committee. He has also been recognized as a top attorney by SD METRO Magazine and a leader in law by the San Diego Business Journal.

PANELISTS

Lu Yin, CEO, Persperion Diagnosics Inc.

Lu Yin received his Ph.D. in nanoengineering at the University of California San Diego. During over 8 years of research, Lu has published over 40 articles and patents on his research on non-invasive biosensors, batteries, and integrated wearable systems, many of which are covered by mainstream media and are actively implemented in industrial applications. In 2022, Lu founded the company Persperion Diagnostics Inc., aiming to use a novel non-invasive touch-based sweat biomarker sensing technology to help over 500 million diabetes users to live happier and healthier lives, starting with replacing the painful and inconvenient fingerprick glucose sensors.

Sanket Agrawal, CEO, 1859

Sanket Agrawal is a seasoned and science-forward biopharma leader who joined 1859 as CEO in April 2023. He brings deep experience in building global organizations, driving growth and commercial strategies for novel therapeutics and diagnostics. At 1859, Sanket leads a talented, multidisciplinary team dedicated to disrupting small molecule drug discovery by powering AIML with unique proprietary empirical data, a true convergence of biology and in silico. Prior to 1859, Sanket served as CBO at Foundation Medicine, a pioneering cancer genomics company, where he led the largest biopharma business in the sector and partnered with biopharma companies to advance cancer research and therapeutics. He held various executive roles at Amgen for nearly 15 years, most recently as General Manager for KRAS, where he led the rapid development and launch of the first ever targeted therapy for KRAS-mutant non-small cell lung cancer. Sanket holds an MBA from UCLA, an MPH from the University of Liverpool, and an M.Eng. in Information Systems from the University of Toronto.

Rubén Flores, Academic Partnerships and Corporate Business Development Lead, General Inception

Rubén Flores-Saaib is the Academic Partnerships and Corporate Business Development Lead at General Inception, working with Venture Capital investors to create new companies. He began his career as a Scientist at BD, before moving to Biosite (now Abbott) and then joining Chemicon to lead the Luminex Multiplex and Diagnostics teams. Rubén has also held management positions on the business development teams at Millipore and Merck and subsequently served as Vice President of Marketing and Product Development at Genway Biotech. Rubén has also served as an academic leader for technology licensing, serving as Vice President for Business Development at LA BioMed (now the Lundquist Institute), Director at UC San Diego, and most recently as Associate Director of Licensing at the University of Southern California. In addition, Rubén is an entrepreneur and serves as Interim CEO of Regain Biomedicals. Rubén received his Ph.D. from UCLA’s Department of Chemistry and Biochemistry.

Andrew Jackson, former CFO, Eterna Therapeutics

Mr. Andrew Jackson is a financial executive with over 25 years of corporate finance/accounting experience with success in publicly traded companies and venture capital backed startups. Mr. Jackson most recently served as CFO of Eterna Therapeutics. Prior to his position at Eterna Therapeutics, Mr. Jackson served as the Chief Financial Officer of Ra Medical Systems, Inc. from April 2018 until May 2022, and as its Secretary from August 2021 to May 2022. From October 2016 to April 2018, he was Chief Financial Officer for AltheaDx, Inc, a molecular diagnostics company specializing in precision medicine. From March 2014 to March 2016, Mr. Jackson held senior financial positions, including Chief Financial Officer, at Celladon Corporation, a publicly traded, clinical stage biotechnology company. From April 2013 to March 2014, he held senior financial positions at Sapphire Energy, an industrial biotechnology company. Mr. Jackson received a MSBA in Finance in December 2006 from San Diego State University and a BSB in Accounting in June 1992 from the University of Minnesota.

About EvoNexus

EvoNexus is California’s leading nonprofit technology startup incubator located in San Diego. EvoNexus has successfully incubated over 260 startups with a survival rate of over 85%. Since the incubator’s formation in 2010, EvoNexus companies have secured over $1.6B in venture funding, $10B in pre-exit valuation, and had over 45 acquisitions valued at over $2.1B. YTD $240M invested. EvoNexus is supported by corporate partners, including some of the largest multinational corporations in the world such as Qualcomm, Viasat, muRata, pSemi, and more! For more information, please visit evonexus.org.

About Wilson Sonsini Goodrich & Rosati

Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them.

The firm is nationally recognized as a leader in the fields of corporate governance and finance, mergers and acquisitions, private equity, securities litigation, employment law, intellectual property, and antitrust, among many other areas of law. Our distinguished international roster of clients spans a wide variety of industries, including information technology, life sciences, energy and clean technology, social and traditional media, communications, retail, and financial services.

Register Here!

Venue

EvoNexus
5015 Shoreham Place
San Diego, CA 92122 United States
+ Google Map
Phone
7609163321
View Venue Website